title: Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer.
abstract: Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) is a promising cancer therapeutic target due to its selective apoptosis-inducing effect in cancer cells. To efficiently deliver TRAIL to the tumor cells, an oncolytic adenovirus (p55-hTERT-HRE-TRAIL) carrying the TRAIL coding sequence was constructed. In the present study, we aimed to investigate the effect of p55-hTERT-HRE-TRAIL on the growth and metastasis of triple-negative breast cancer (TNBC). We observed that infection of the recombinant adenovirus resulted in expression of TRAIL and massive cell death in a TNBC cell line MDA-MB-231. This effect is much weaker in MCF-10A, which is a normal breast cell line. Administration of P55-HTERT-HRE-TRAIL significantly reduced orthotopic breast tumor growth and extended survival in a metastatic model. Our results suggest the oncolytic adenovirus armed with P55-HTERT-HRE-TRAIL, which exhibited enhanced anti-tumor activity and improved survival, is a promising candidate for virotherapy of TNBC.
authors.affiliation: Department of General Surgery; Zhongshan Hospital; Fudan University, Shanghai, PR China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhu
authors.forename: Hongwei
authors.initials: H
authors.lastname: Zhang
authors.forename: Yi
authors.initials: Y
authors.lastname: Shi
authors.forename: Mangen
authors.initials: M
authors.lastname: Song
authors.forename: Bijun
authors.initials: B
authors.lastname: Zhu
authors.forename: Lai
authors.initials: L
authors.lastname: Wei
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology; D017209:Apoptosis; D018270:Carcinoma, Ductal, Breast / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D050130:Oncolytic Virotherapy; D050504:Oncolytic Viruses / Q000235:genetics* / Q000502:physiology; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics / Q000378:metabolism*; D064726:Triple Negative Breast Neoplasms / Q000473:pathology* / Q000628:therapy
chemical_list: D053221:TNF-Related Apoptosis-Inducing Ligand
keywords: adenovirus; triple-negative breast cancer (TNBC); tumor necrosis factor-related apoptosis inducing ligand (TRAIL); virotherapy
references.citation: Mol Ther. 2001 Sep;4(3):257-66
references.pmid: 11545617
references.citation: Cancer Res. 2003 May 15;63(10):2369-72
references.pmid: 12750253
references.citation: Cancer Res. 2001 Apr 15;61(8):3330-8
references.pmid: 11309289
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: J Gene Med. 2007 Jun;9(6):440-51
references.pmid: 17410615
references.citation: Mol Biol Rep. 2010 Oct;37(7):3239-47
references.pmid: 19876766
references.citation: Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1754-9
references.pmid: 10677530
references.citation: J Exp Clin Cancer Res. 2012 May 28;31:51
references.pmid: 22640485
references.citation: Cell Res. 2006 Aug;16(8):740
references.pmid: 16915293
references.citation: N Engl J Med. 2009 Aug 13;361(7):653-63
references.pmid: 19675329
references.citation: J Pharm Pract. 2012 Jun;25(3):319-23
references.pmid: 22551559
references.citation: Science. 1998 Aug 28;281(5381):1305-8
references.pmid: 9721089
references.citation: Ann Surg. 2010 Jun;251(6):1079-86
references.pmid: 20485131
references.citation: Clin Cancer Res. 2004 Aug 15;10(16):5299-312
references.pmid: 15328165
references.citation: Mol Cancer Ther. 2007 Apr;6(4):1387-99
references.pmid: 17431117
references.citation: Nat Rev Cancer. 2002 Jun;2(6):420-30
references.pmid: 12189384
references.citation: Gene Ther. 2003 Apr;10(7):540-9
references.pmid: 12646859
references.citation: Am J Cancer Res. 2012;2(1):75-92
references.pmid: 22206047
references.citation: Life Sci. 2008 Jun 6;82(23-24):1154-61
references.pmid: 18485417
references.citation: Mol Cancer Ther. 2005 Dec;4(12):2026-36
references.pmid: 16373718
references.citation: Clin Cancer Res. 2006 Sep 1;12(17):5224-30
references.pmid: 16951242
references.citation: Cancer Gene Ther. 2007 Mar;14(3):316-26
references.pmid: 17186015
references.citation: Cancer. 2007 May 1;109(9):1721-8
references.pmid: 17387718
references.citation: Breast Cancer Res Treat. 2009 Jan;113(2):217-30
references.pmid: 18266105
references.citation: Mol Cancer Ther. 2009 Aug;8(8):2096-102
references.pmid: 19671759
references.citation: J Clin Invest. 1999 Jul;104(2):155-62
references.pmid: 10411544
references.citation: Immunity. 2000 Jun;12(6):599-609
references.pmid: 10894160
references.citation: Viruses. 2010 Jan;2(1):78-106
references.pmid: 20543907
references.citation: Adv Cancer Res. 2009;103:43-73
references.pmid: 19854352
references.citation: Clin Oncol (R Coll Radiol). 2011 Nov;23(9):587-600
references.pmid: 21524569
references.citation: Cancer Res. 1999 Feb 1;59(3):734-41
references.pmid: 9973225
references.citation: J Pharmacol Exp Ther. 2001 Oct;299(1):31-8
references.pmid: 11561060
references.citation: Neoplasia. 2007 May;9(5):435-42
references.pmid: 17534449
references.citation: Adv Drug Deliv Rev. 2009 Jul 2;61(7-8):572-88
references.pmid: 19393705
references.citation: Curr Cancer Drug Targets. 2007 Mar;7(2):181-9
references.pmid: 17346110
references.citation: Leukemia. 1999 Nov;13(11):1817-24
references.pmid: 10557057
references.citation: BMC Cancer. 2005 Jan 14;5:5
references.pmid: 15651986
references.citation: Hum Gene Ther. 2010 Jul;21(7):855-64
references.pmid: 20163249
references.citation: Clin Cancer Res. 2006 Nov 1;12(21):6523-31
references.pmid: 17085667
references.citation: Breast Cancer (Auckl). 2010 May 20;4:35-41
references.pmid: 20697531
references.citation: Nat Med. 2001 Jan;7(1):94-100
references.pmid: 11135622
references.citation: Clin Cancer Res. 2001 May;7(5):1362-9
references.pmid: 11350907